Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7690MR)

This product GTTS-WQ7690MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in B-cell malignancies research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7690MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6513MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ6812MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ9530MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ11841MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ13273MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ2140MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ15356MR IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TRC-105
GTTS-WQ13474MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRS-343
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW